CureVac announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac’s RNActive technology.
RNActive vaccines, based on CureVac’s technology platform, have already demonstrated effectiveness and safety in several clinical trials. CureVac’s preclinical influenza studies, which were published in Nature Biotechnology in December 2012, have formed an important basis for this collaboration.
Under the terms of the collaboration, CureVac will develop optimized RNActive vaccines based on Crucell’s proprietary antigen sequences which will be tested in various models.
Additional details of the collaboration were not disclosed.
Date: October 3, 2013
Filed Under: Drug Discovery